

Special Issue

Personalized Therapy of Asthma

Message from the Guest Editor

Dear colleagues, Asthma is a complex multidisciplinary disease characterized by airway inflammation and remodelling, which is frequently misdiagnosed and underrecognized, thus affecting both public health and the patient's quality of life. Despite many available treatments and adequate therapeutic compliance, some patients still complain of an uncontrolled, difficult to treat asthma. This has stimulated physicians and researchers to progressively improve their knowledge and identify different asthma phenotypes. The introduction of biologic therapies as add-on treatment in severe asthma has further increased the need of novel biomarkers and asthma clustering, making the determination of asthma endotypes a key point for a tailored approach. We are pleased to invite you to contribute to this special issue about personalized treatment for asthma. The aim of this special issue is to provide new evidence for asthma phenotyping, by finding new roles to the well-known biomarkers, as FeNO, blood eosinophils and inflammatory cytokines, and proposing new approaches in the pipeline. I look forward to receiving your contributions.

Guest Editor

Dr. Luisa Brussino

Department of Medical Sciences, University of Turin, 10124 Torino, Italy

Deadline for manuscript submissions

closed (25 January 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/75349

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).